linkedin post 2014-05-06 06:16:04

Uncategorized
JAPAN'S WORLD LEADERSHIP IN STEM CELLS has resulted in part from having a Nobel winner on the subject (Shinya Yamanaka MD PhD), but also by mobilization of investments and legal framework behind this remarkable innovation. The Innovation Network Corporation of Japan (INCJ), recently assembled a promising new company around the work. http://www.megakaryon.com/index-e.html View in LinkedIn
Read More

linkedin post 2014-05-09 17:42:53

Uncategorized
iPS TO MAKE PLATELETS. "The donor-dependent supply of platelets is frequently insufficient to meet transfusion needs ... we developed a clinically applicable strategy for the derivation of functional platelets from human pluripotent stem cells (PSCs). This approach involves the establishment of stable immortalized megakaryocyte progenitor cell lines." http://lnkd.in/dyhcv7G View in LinkedIn
Read More

linkedin post 2014-05-06 05:58:48

Uncategorized
GROUNDBREAKING FIRST HUMAN iPS TRIAL. "World’s first induced pluripotent stem cells clinical study on humans launches in Japan. Earlier this year doctors announced success in restoring sight to a man suffering from macular degeneration by treating him with stem cells derived from human embryos." http://stemcellstm.alphamedpress.org/site/misc/News159.xhtml View in LinkedIn
Read More

linkedin post 2014-05-08 05:07:35

Uncategorized
HUMAN PLURIPOTENT CELL BANKS. "The mission of the International Stem Cell Registry is to provide a searchable, comprehensive database that includes published and validated unpublished information on human embryonic (hESC) and disease-specific induced pluripotent (iPS) stem cell lines." http://lnkd.in/dNaD3RV View in LinkedIn
Read More

linkedin post 2014-05-06 05:55:52

Uncategorized
POC: STEM CELLS CURE MOUSE EYE DISEASE. "Just last month a team of doctors ... reported how they had taken stem cells from mice embryos, “turned” them into photoreceptors in the lab and then used them to restore sight in adult mice." This is truly the start of space age medicine. http://stemcellstm.alphamedpress.org/site/misc/News159.xhtml View in LinkedIn
Read More

linkedin post 2014-05-08 05:05:37

Uncategorized
NEGLIGIBLE TUMOR FEARS WITH iPS. "Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible." http://lnkd.in/dpPjkpG View in LinkedIn
Read More

linkedin post 2014-05-05 04:26:54

Uncategorized
SHORT-LIVED STEM CELLS. "There is general acceptance that mesenchymal cells, cord blood, adipose tissues and other adult stem cell sources often do not survive for more than a few weeks in patients, and their effects are most likely through growth factor release, host inflammatory responses and vascular alterations rather than replacing tissues lost in the disease." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn
Read More

linkedin post 2014-05-08 05:03:03

Uncategorized
iPS BACKGROUND. "Traditionally, scientists have worked with both embryonic and adult stem cells as research tools ... Although some adult stem cells do have differentiation capacity, it is often limited in nature, which creates narrow options for use. Thus, induced pluripotent stem cells represent a promising combination of adult and embryonic stem cell characteristics." http://www.prnewswire.com/news-releases/complete-2014-induced-pluripotent-stem-cell-ipsc-industry-report-245515681.html View in LinkedIn
Read More

linkedin post 2014-05-05 04:24:04

Uncategorized
iPS IN OTHER DISEASES. "Although cells that release insulin in response to glucose can be produced, they appear very frail ... A similar story is found for human iPSC-derived cardiomyocytes that can definitely beat in the culture dish ... but do not display all of the expected phenotypes of mature cells." http://hmg.oxfordjournals.org/content/early/2013/08/19/hmg.ddt379.full View in LinkedIn
Read More